Vericel (VCEL) Chief Medical Officer Mark Buys $149K of Stock

Vericel Insider Activity Includes Chief Medical Officer Purchase

Vericel Corporation (NasdaqGM: VCEL) saw notable insider transactions in late June, led by Chief Medical Officer Jonathan Mark Hopper acquiring 5,000 shares on June 26, 2026. The purchase was executed at a price of $29.82 per share, bringing the total value of the transaction to $149,100. This trade adds to a flurry of recent buying and selling activity among key executives at the Burlington-based biopharmaceutical firm.

More Insider Trades at Vericel Corporation

Leadership movement during June included several other key figures at the company. On June 26, 2026, Chief Legal Officer Sean Flynn picked up 15,000 shares at $16.25 apiece for a total value of $243,750. Principal Accounting Officer Jonathan Siegal also made moves on June 26, 2026, buying 2,500 shares at $29.82 each for $74,550 and selling 2,732 shares in a planned transaction at $44.90 each for a total of $122,666.80. Earlier in the month on June 18, 2026, Sean Flynn sold 15,000 shares at $40.21 under a pre-arranged trading plan, while Chief Operating Officer Michael Halpin acquired 10,000 shares on the same day.

Vericel Stock Performance and Valuation

Vericel shares trade around $44.49, sitting within a 52-week range spanning from a low of $28.95 to a high of $49.32. The company holds a market capitalization of roughly $2.03 billion and features a price-to-earnings ratio of 82.40 alongside a forward P/E ratio of 46.75. Other fundamental metrics include a beta of 1.05, a quick ratio of 4.53, and a debt-to-equity ratio of 25.17.

Recent Earnings Results for Vericel

For its financial performance, the biopharmaceutical company reported annual revenue of $306.30 million with a revenue growth rate of 22.5%. Earnings per share stood at $0.48, accompanied by a net margin of 7.91% and a return on equity of 7.16%. The company's next earnings report is scheduled for November 5, 2026.

Analysts Set New Price Targets

Covering financial firms maintain a positive outlook on the stock, which carries a consensus recommendation of strong buy from seven analysts. Truist Securities maintained its buy rating on October 14, 2026, while adjusting its price target to $52.00 from $58.00. Earlier on July 31, 2026, TD Cowen maintained a buy rating and raised its target to $58.00 from $55.00, Truist Securities reiterated a buy rating with a $58.00 target, and HC Wainwright & Co. maintained a buy rating with a $72.00 target. Price targets across the covering firms feature a high of $72.00 and a low of $55.00, with a mean target of $60.57.

About Vericel Corporation

Vericel Corporation operates as a commercial-stage biopharmaceutical firm focused on developing and distributing cellular therapies and specialty biologic products. Headquartered in Burlington, Massachusetts, the company serves sports medicine and severe burn care markets with treatments such as MACI for knee cartilage repair, Epicel for deep skin replacements, and NexoBrid for eschar removal in burn patients.

Looking Ahead at Insider Disclosures

Investors monitoring Vericel will likely watch upcoming filing disclosures and the next scheduled earnings update on November 5, 2026, to gauge ongoing operational momentum. Insider transactions offer a look into how individual executives manage their personal equity holdings, though these filings reflect past decisions rather than explicit market signals.